Growth inhibition of mammalian cells by eosinophil cationic protein.
暂无分享,去创建一个
D. Salomon | M. Seno | M. Kitazoe | M. Ueda | R. de Llorens | T. Maeda | H. Tada | H. Yamada
[1] M. Seno,et al. Preparation of potent cytotoxic ribonucleases by cationization: enhanced cellular uptake and decreased interaction with ribonuclease inhibitor by chemical modification of carboxyl groups. , 2001, Biochemistry.
[2] J. Pous,et al. Three-dimensional crystal structure of human eosinophil cationic protein (RNase 3) at 1.75 A resolution. , 2000, Journal of molecular biology.
[3] M. Seno,et al. Targeting activated lymphocytes with an entirely human immunotoxin analogue: human pancreatic RNase1-human IL-2 fusion. , 2000, Cytokine.
[4] E. Boix,et al. Crystal structure of eosinophil cationic protein at 2.4 A resolution. , 1999, Biochemistry.
[5] Jianzhi Zhang,et al. Rapid Evolution of the Ribonuclease A Superfamily: Adaptive Expansion of Independent Gene Clusters in Rats and Mice , 1999, Journal of Molecular Evolution.
[6] M. Seno,et al. Inhibition of cell growth by a fused protein of human ribonuclease 1 and human basic fibroblast growth factor. , 1999, Protein engineering.
[7] S. Schwarze,et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. , 1999, Science.
[8] M. Lindsay,et al. Pharmacology of the eosinophil. , 1999, Pharmacological reviews.
[9] D. Newton,et al. Unique recombinant human ribonuclease and inhibition of Kaposi's sarcoma cell growth. , 1998, Journal of the National Cancer Institute.
[10] M. Seno,et al. Human pancreatic RNase1-human epidermal growth factor fusion: an entirely human 'immunotoxin analog' with cytotoxic properties against squamous cell carcinomas. , 1998, Protein engineering.
[11] I. Pastan,et al. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. , 1998, Trends in biotechnology.
[12] H. Rosenberg,et al. The eosinophil ribonucleases , 1998, Cellular and Molecular Life Sciences CMLS.
[13] K. Dyer,et al. Diversity among the primate eosinophil-derived neurotoxin genes: a specific C-terminal sequence is necessary for enhanced ribonuclease activity. , 1997, Nucleic acids research.
[14] M. Seno,et al. Tissue-specific expression of pancreatic-type RNases and RNase inhibitor in humans. , 1997, DNA and cell biology.
[15] M. Libonati,et al. Structure–function relationships in human ribonucleases: main distinctive features of the major RNase types , 1997, FEBS letters.
[16] E. Olson,et al. Two highly homologous ribonuclease genes expressed in mouse eosinophils identify a larger subgroup of the mammalian ribonuclease superfamily. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[17] A. Prochiantz,et al. Cell Internalization of the Third Helix of the Antennapedia Homeodomain Is Receptor-independent* , 1996, The Journal of Biological Chemistry.
[18] M. Seno,et al. Recombinant human pancreatic ribonuclease produced in E. coli: importance of the amino-terminal sequence. , 1995, Biochemical and biophysical research communications.
[19] H. Rosenberg. Recombinant Human Eosinophil Cationic Protein , 1995, The Journal of Biological Chemistry.
[20] M. Seno,et al. Nucleotide sequence encoding human pancreatic ribonuclease. , 1994, Biochimica et biophysica acta.
[21] B. Geiger,et al. Suppression of vinculin expression by antisense transfection confers changes in cell morphology, motility, and anchorage-dependent growth of 3T3 cells , 1993, The Journal of cell biology.
[22] M. Kanehisa,et al. A knowledge base for predicting protein localization sites in eukaryotic cells , 1992, Genomics.
[23] B. Geiger,et al. Suppression of tumorigenicity in transformed cells after transfection with vinculin cDNA , 1992, The Journal of cell biology.
[24] P. Leder,et al. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. , 1992, Science.
[25] R. L. Barker,et al. In vitro killing of microfilariae of Brugia pahangi and Brugia malayi by eosinophil granule proteins. , 1990, Journal of immunology.
[26] R. L. Barker,et al. Eosinophil cationic protein cDNA. Comparison with other toxic cationic proteins and ribonucleases. , 1989, Journal of immunology.
[27] T. Ganz,et al. Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. , 1989, Journal of immunology.
[28] D. Loegering,et al. Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. , 1989, The American review of respiratory disease.
[29] R. Dahl,et al. Extracellular deposit of the cationic proteins ECP and EPX in tissue infiltrations of eosinophils related to tissue damage , 1988, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[30] H. Jörnvall,et al. Purification and characterization of eosinophil cationic protein from normal human eosinophils , 1988, European journal of haematology.
[31] G. Gleich,et al. Toxic effects produced or mediated by human eosinophil granule components on Trypanosoma cruzi. , 1988, The American journal of tropical medicine and hygiene.
[32] T. Hiratsuka. Selective fluorescent labeling of the 50-, 26-, and 20-kilodalton heavy chain segments of myosin ATPase. , 1987, Journal of biochemistry.
[33] R. L. Barker,et al. Comparative toxicity of purified human eosinophil granule proteins for newborn larvae of Trichinella spiralis. , 1987, The Journal of parasitology.
[34] M. Yazdanbakhsh,et al. Synergism between eosinophil cationic protein and oxygen metabolites in killing of schistosomula of Schistosoma mansoni. , 1987, Journal of immunology.
[35] J. Tavernier,et al. Killing of Plasmodium falciparum by eosinophil secretory products , 1987, Infection and immunity.
[36] D. Loegering,et al. Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. , 1986, Journal of immunology.
[37] P. Venge,et al. Mechanism of membrane damage mediated by human eosinophil cationic protein , 1986, Nature.
[38] D. Loegering,et al. Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[39] D. Loegering,et al. Comparative toxicity of purified human eosinophil granule cationic proteins for schistosomula of Schistosoma mansoni. , 1985, The American journal of tropical medicine and hygiene.
[40] R. Dahl,et al. The Gordon phenomenon induced by the eosinophil cationic protein and eosinophil protein X. , 1982, The Journal of allergy and clinical immunology.
[41] I. Olsson,et al. Morphological studies on the killing of schistosomula of Schistosoma mansoni by human eosinophil and neutrophil cationic proteins in vitro , 1981, Parasite immunology.
[42] E. Ben-hur,et al. Characterization of the response of a human breast carcinoma cell line (T-47D) to radiation and chemotherapeutic agents. , 1981, Israel journal of medical sciences.
[43] J. Bertram,et al. Establishment of a cloned line of Lewis Lung Carcinoma cells adapted to cell culture. , 1980, Cancer letters.
[44] S. M. Sumi,et al. Neurotoxicity of human eosinophils. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[45] C. Gahmberg,et al. K562—A human erythroleukemic cell line , 1979, International journal of cancer.
[46] S. Collins,et al. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture , 1977, Nature.
[47] S. von Kleist,et al. Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor. , 1975, Journal of the National Cancer Institute.
[48] F. O'Neill. Control of nuclear division in SV40 and adenovirus type 12 transformed mouse 3T3 cells , 1975, International journal of cancer.
[49] S. Aaronson,et al. Development of 3T3‐like lines from Balb/c mouse embryo cultures: Transformation susceptibility to SV40 , 1968, Journal of cellular physiology.
[50] N. Green,et al. The reactivity toward N-bromosuccinimide of tryptophan in enzymes, zymogens, and inhibited enzymes. , 1966, Biochemistry.
[51] G. Waksman,et al. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. , 2001, Cancer research.
[52] M. Desantis,et al. Purification and characterization of a recombinant human cripto-1 protein. , 1998, Growth factors.
[53] S. Brunak,et al. SHORT COMMUNICATION Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites , 1997 .
[54] J. Folkman,et al. Human betacellulin, a member of the EGF family dominantly expressed in pancreas and small intestine, is fully active in a monomeric form. , 1996, Growth factors.
[55] D. Pardoll. Paracrine cytokine adjuvants in cancer immunotherapy. , 1995, Annual review of immunology.